Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ ) 0.5752 -0.0248 (-4.13%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 472,283 Open 0.6310 Bid (Size) 0.5800 (6) Ask (Size) 0.6000 (5) Prev. Close 0.6000 Today's Range 0.5050 - 0.6400 52wk Range 0.5501 - 5.010 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate June 05, 2024 Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate Via News Direct Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon June 04, 2024 On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co... Via Benzinga Performance YTD -50.84% -50.84% 1 Month -7.00% -7.00% 3 Month -42.48% -42.48% 6 Month -45.74% -45.74% 1 Year -87.39% -87.39% More News Read More 12 Health Care Stocks Moving In Tuesday's Pre-Market Session June 04, 2024 Via Benzinga Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 June 03, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Reports Results of 2024 Annual General Meeting May 31, 2024 From Mainz BioMed NV Via GlobeNewswire Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket May 29, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday May 29, 2024 Via InvestorPlace Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting May 28, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial May 20, 2024 From Mainz BioMed NV Via GlobeNewswire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday May 17, 2024 Via InvestorPlace Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game May 16, 2024 Via Benzinga Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. May 07, 2024 From Mainz BioMed NV Via GlobeNewswire mRNA Is Promising A Breakthrough In Fighting Cancer April 29, 2024 Via Benzinga Exposures COVID-19 Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic April 25, 2024 From Mainz BioMed NV Via GlobeNewswire The Pharmaceutical Industry Finds Itself At A Historical Crossroads April 10, 2024 Via Benzinga MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023 April 09, 2024 Via InvestorPlace Mainz Biomed Reports Full Year 2023 Financial Results April 09, 2024 From Mainz BioMed NV Via GlobeNewswire Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era April 02, 2024 Via Benzinga Exposures COVID-19 Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment March 19, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options March 18, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations March 12, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic March 05, 2024 From Mainz BioMed NV Via GlobeNewswire Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening February 28, 2024 Via Benzinga Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community February 27, 2024 From Mainz BioMed NV Via GlobeNewswire Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment February 22, 2024 Via Benzinga Topics Intellectual Property Exposures COVID-19 Intellectual Property Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
